UMOVY ACIDO HIALURONICO — Class I drug recall D-0493-2025
Completed recall by Umary-USA.com, reported 2025-06-25, distributed nationwide. Marketed without approved NDA/ANDA- Laboratory analysis found product to be tainted with undeclared ingredient
| Recall number | D-0493-2025 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Completed |
| Voluntary or mandated | Voluntary |
| Recalling firm | Umary-USA.com, Nogales, AZ, United States |
| Recall initiated | 2025-05-21 |
| Classified | 2025-06-24 |
| Reported by FDA | 2025-06-25 |
| Distributed | Nationwide (US) |
| Reason classes | undeclared allergen, unapproved product |
| UPC / GTIN / UDI-DI | 07503046054134 |
Product
UMOVY ACIDO HIALURONICO, Conenido: 30 capletas de 850mg, distribuido por: EREN NATURAL S.A. DE C.V, Zappan, Jal. C.P, UPC 7503046054134
Reason for recall
Marketed without approved NDA/ANDA- Laboratory analysis found product to be tainted with undeclared ingredients: Dexamethasone and Diclofenac.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0493-2025. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.